Immunotec Reports First Quarter Results

VAUDREUIL-DORION, QUEBEC–(Marketwired – March 27, 2017) – Immunotec Inc. (TSX VENTURE:IMM), a direct-to- consumer company and leader in the nutritional industry (the “Company” or “Immunotec”), today announced its first quarter financial results for Fiscal 2017. All amounts in this press release are in Canadian dollars unless otherwise indicated.

“Our first quarter 2017 results included strong sales volume performances in major markets and a significant improvement in Adjusted EBITDA when compared to last year,” said Charles Orr, Chief Executive Officer.


  • Network sales amounted to $28.9M, an increase of 37.0% over last year, while sponsoring1 of new customers and consultants increased by 44.5% over last year.
  • Network sales in key markets grew by 101.6% in Mexico, 9.1% in the United States and 3.0% in Canada.
  • Margin before expenses increased by 1.5%, to 76.0%, and Adjusted EBITDA1amounted to 6.8% of revenues, mainly due to the recent price increase, the favorable exchange rate with the US dollar, and a volume rebate from one of the suppliers.
  • Net profit totalled $0.7M or $0.01 basic and fully diluted profit per common share.

Under the leadership of Mr. Mauricio Domenzain in partnership with Nexxus Capital of Mexico, on March 22, 2017, the Company announced that it had entered into a definitive arrangement agreement with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V., to acquire all of the issued and outstanding common shares of the Company for a cash consideration of $0.485 per Share. “This follows a strategic review process that was initiated last year. The transaction represents an attractive value for our shareholders and an important vote of confidence for our consultants, employees and for all our other stakeholders,” said Mr. Orr.

Results of operations
For the three-month periods ended January 31,
(‘000s of C$, except for share and per share data) 2017 2016
Revenues 30,784 22,944
Cost of sales 7,400 5,851
Margin before expenses 23,384 17,093
Expenses 21,465 16,535
Operating income 1,919 558
Net finance expenses 765 5
Income taxes 424 215
Net profit 730 338
Total comprehensive income 213 316
Total basic and diluted net profit
per common share 0.010 0.005
Weighted average number of
common shares outstanding
during the period
Basic 69,761,378 69,287,627
Diluted 70,197,926 69,289,931
Revenues and sponsoring 1
For the three-month periods ended January 31,
(‘000s of C$) 2017 2016 Variation
Network sales 28,940 21,130 37.0%
Other revenue 1,844 1,814 1.6%
30,784 22,944 34.2%
Network sales in key markets in local currency 2017 2016 Variation
Mexico (‘000s of Mexican pesos) 272,826 135,299 101.6%
United States (‘000s of US$) 5,877 5,388 9.1%
Canada (‘000s of C$) 2,916 2,831 3.0%
Sponsoring1of new customers and consultants in
key markets (# of people) 2017 2016 Variation
Mexico 23,662 14,077 68.1%
United States 3,768 4,297 -12.3%
Canada 1,957 1,957 0.0%
29,387 20,331 44.5%
Calculation of adjusted EBITDA1
For the three-month periods ended January 31,
(‘000s of C$) 2017 2016
Net profit 730 338
Depreciation and amortization 174 180
Net finance expenses 765 5
Other expenses 12 515
Income taxes 424 215
Adjusted EBITDA 2,105 1,252
as a % of Revenues 6.8% 5.5%

About Immunotec Inc.

Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive family of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance.

Please visit us at for additional information.

The Company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at and on the Company’s website at The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Press Release should be read in conjunction with the Company’s most recent unaudited interim condensed consolidated financial statements and the Management discussion and analysis which can be found at


Certain statements contained in this news release are forward looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec’s most recent Management’s Discussion, which can be found at Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.


This Press Release contains non-GAAP measures which do not have a standardized meaning under International Financial Reporting Standards (“IFRS”). We use earnings before interest, taxes, depreciation and amortization (“EBITDA”), as this measure allows management to evaluate the operational performance of the Company. EBITDA does not have any standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other issuers. EBITDA should not be considered an alternative to profit (loss) in measuring the Company’s performance, nor should it be used as an exclusive measure of cash flow. This measure does not represent the funds available for the repayment of debt, the payment of dividends, reinvestment or other discretionary uses, and should not be considered in isolation or as substitutes for other measures of performance calculated according to IFRS.

Adjusted EBITDA and Sponsoring

  • Adjusted EBITDA corresponds to EBITDA as defined above less elements that management considers to be outside the scope of its normal activities and therefore not reflective of how management views performance measurement. Management believes that this metric is necessary in order to isolate its commercial operations from items which it believes merit separate examination when assessing performance. Consistent improvement in adjusted EBITDA is one of management’s primary objectives.
  • Sponsoring means the activity in which independent Consultants sponsor new Consultants and Customers; the sponsored Consultants themselves may sponsor new Consultants or Customers and so forth. This is referred to as a Consultant’s “organization” or “downline”. The Consultants are compensated for sales generated by their organization, based on their qualification and rank. Successful Independent Consultants assume the responsibility to train, support and communicate with their downline. The Consultants are not compensated on by simply referring or inviting new people to joint without them making a purchase.

1 Refer to the “NON-GAAP MEASURES” section. The definition of Sponsoring and the Adjusted EBITDA reconciliation to Net profit is shown below.

Immunotec Inc.
Patrick Montpetit, CPA, CA, CF
Vice-President and Chief Financial Officer
(450) 510-4527